The Effect of Platelet Activity, ABCB1 Genetic Polymorphism, and Renal Function on the Development of Ticagrelor-Related Dyspnea in Patients with Acute Coronary Syndrome

References

• Collet JP. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. In: European Heart Journal. Vol. 42. Oxford University Press;2021:1289–1367. doi:10.1093/eurheartj/ehaa575
   Google Scholar
• Lawton JS, Lawton JS, Tamis-Holland JE, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. J Am Coll Cardiol. 2022;79(2):e21–e129. doi:10.1016/j.jacc.2021.09.006
   PubMedGoogle Scholar
• Ibanez B. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. In: European Heart Journal. Vol. 39. Oxford University Press;2018:119–177. doi:10.1093/eurheartj/ehx393
   Google Scholar
• Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes.. Eur Heart J. 2023;44(38):3720–3826. doi:10.1093/eurheartj/ehad191
   PubMed Web of Science ®Google Scholar
• Bálint A, Tornyos D, El Alaoui El Abdallaoui O, Kupó P, Komócsi A. Network meta-analysis of ticagrelor for stroke prevention in patients at high risk for cardiovascular or cerebrovascular events. Stroke. 2021;52(9):2809–2816. doi:10.1161/STROKEAHA.120.032670
   PubMed Web of Science ®Google Scholar
• Nawarskas JJ, Clark SM. Ticagrelor: a novel reversible oral antiplatelet agent. Cardiol Rev. 2011;19(2):95–100. doi:10.1097/CRD.0b013e3182099d86
   PubMed Web of Science ®Google Scholar
• Teng R. Ticagrelor: pharmacokinetic, pharmacodynamic and pharmacogenetic profile: an update. In: Clinical Pharmacokinetics. Vol. 54. Springer International Publishing;2015:1125–1138. doi:10.1007/s40262-015-0290-2
   Google Scholar
• Li Y, Landqvist C, Grimm SW. Disposition and metabolism of ticagrelor, a novel P2Y 12 receptor antagonist, in mice, rats, and marmosets. Drug Metab Dispos. 2011;39(9):1555–1567. doi:10.1124/dmd.111.039669
   PubMed Web of Science ®Google Scholar
• Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010;38(9):1514–1521. doi:10.1124/dmd.110.032250
   PubMed Web of Science ®Google Scholar
• Wang X, Xi S, Liu J, et al. Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patients. Euro Heart J Suppl. 2016;18:F19–F26. doi:10.1093/eurheartj/suw034
   PubMed Web of Science ®Google Scholar
• Cakal S, Cakal B, Güven Z, et al. Switching ticagrelor to 600 mg or 300 mg clopidogrel loading bridge in patients with unstable angina. J Clin Med. 2021;10(11). doi:10.3390/jcm10112463
   Web of Science ®Google Scholar
• Arora S. Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week. J Am Colle Cardiol. 2019;73(19):2454–2464. doi:10.1016/j.jacc.2019.03.470
   PubMed Web of Science ®Google Scholar
• Storey RF. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol. 2010;56(3):185–193. doi:10.1016/j.jacc.2010.01.062
   PubMed Web of Science ®Google Scholar
• Wang Y. Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA. N Engl J Med. 2021;385(27):2520–2530. doi:10.1056/nejmoa2111749
   PubMed Web of Science ®Google Scholar
• Armstrong M. Articles Eff ect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376:1320–1328. doi:10.1016/S0140
   PubMed Web of Science ®Google Scholar
• Máchal J. CYP2C19 and CYP3A4 activity and ADP-induced platelet reactivity in prasugrel- or ticagrelor-treated STEMI patients: monocentric study in Prague-18 trial participants. Xenobiotica. 2020;50(8):929–938. doi:10.1080/00498254.2020.1731625
   PubMed Web of Science ®Google Scholar
• Dong P, Yang X, Bian S. Genetic polymorphism of CYP2C19 and inhibitory effects of ticagrelor and clopidogrel towards post-percutaneous coronary intervention (PCI) platelet aggregation in patients with acute coronary syndromes. Med Sci Monit. 2016;22:4929–4936. doi:10.12659/MSM.902120
   PubMed Web of Science ®Google Scholar
• Zhu Q. Pharmacokinetic and pharmacogenetic factors contributing to platelet function recovery after single dose of ticagrelor in healthy subjects. Front Pharmacol. 2019;10. doi:10.3389/fphar.2019.00209
   Web of Science ®Google Scholar
• Meskauskaite U, Andruskeviciute S, Ciapiene I, Giedraitiene A, Lesauskaite V, Tatarunas V. Pleiotropic effects of ticagrelor: influence on CYP4F2 gene and protein expression in HUVEC and HepG2, and Escherichia coli bacterial survival. Drug Des Devel Ther. 2022;16:2559–2568. doi:10.2147/DDDT.S357985
   PubMedGoogle Scholar
• Wallentin L. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2009;361(11):1045–1057. doi:10.1056/nejmoa0904327
   PubMed Web of Science ®Google Scholar
• Chen X, Zhou T, Yang D, Lu J. Association between ABCB1 gene polymorphism and renal function in patients with hypertension: a case-control study. Med Sci Monit. 2017;23:3854–3860. doi:10.12659/MSM.902954
   PubMed Web of Science ®Google Scholar
• Bochud M. Association of ABCB1genetic variants with renal function in Africans and in Caucasians. BMC Med Genomics. 2008;1(1). doi:10.1186/1755-8794-1-21
   PubMedGoogle Scholar
• Tamakauskas V. Factors determining ticagrelor-induced dyspnea in patients with acute coronary syndrome. Appl Sci. 2022;12(19). doi:10.3390/app121910021
   Google Scholar
• Thygesen K, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237–269. doi:10.1093/eurheartj/ehy462
   PubMed Web of Science ®Google Scholar
• Wittfeldt A. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol. 2013;61(7):723–727. doi:10.1016/j.jacc.2012.11.032
   PubMed Web of Science ®Google Scholar
• Kallner A, Khatami Z. How does the MDRD Study equation compare with serum creatinine in routine healthcare? Anatomy of MDRD-eGFR. Scand J Clin Lab Invest. 2008;68(sup241):39–45. doi:10.1080/00365510802144789
   PubMed Web of Science ®Google Scholar
• Uhr M, Holsboer F, Mü MB, Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins.
   Google Scholar
• Foote CJ. MDR1 C3435T polymorphisms correlate with cyclosporine levels in de novo renal recipients. Transplant Proc. 2006;38(9):2847–2849. doi:10.1016/j.transproceed.2006.08.120
   PubMed Web of Science ®Google Scholar
• Hauser IA, Koziolek M, Hopfer U, Thévenod F. Therapeutic concentrations of cyclosporine A, but not FK506, increase P- glycoprotein expression in endothelial and renal tubule cells. Kidney Int. 1998;54(4):1139–1149. doi:10.1046/j.1523-1755.1998.00095.x
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo; 1999. Available from: www.pnas.org. Accessed January 18, 2024.
   Google Scholar
• Alsharif KF. Ticagrelor potentiates adenosine-induced stimulation of neutrophil chemotaxis and phagocytosis. Vascul Pharmacol. 2015;71:201–207. doi:10.1016/j.vph.2015.02.006
   PubMed Web of Science ®Google Scholar
• Li X, Wang Q, Xue Y, Chen J, Lv Q. Ticagrelor compared with clopidogrel increased adenosine and cyclic adenosine monophosphate plasma concentration in acute coronary syndrome patients. Basic Clin Pharmacol Toxicol. 2017;120(6):610–614. doi:10.1111/bcpt.12752
   PubMed Web of Science ®Google Scholar
• van Vuren AJ, de Jong B, Bootsma HPR. Ticagrelor-induced renal failure leading to statin-induced rhabdomyolysis. Neth J Med. 2015;2015:4.
   Google Scholar
• Official reprint from UpToDate®. Inhibitors and inducers of P-glycoprotein (P-gp) drug efflux pump (P-gp multidrug resistance transporter); 2022. Available from: https://www.uptodate.com/. Accessed December 18, 2022.
   Google Scholar
• Horn JR, Hansten PD. Ticagrelor Interactions. 2018.
   Google Scholar
• Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J Am Colle Cardiol. 2013;61(25):2495–2502. doi:10.1016/j.jacc.2013.02.058
   PubMed Web of Science ®Google Scholar
• Taubert D. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006;80(5):486–501. doi:10.1016/j.clpt.2006.07.007
   PubMed Web of Science ®Google Scholar
• Yan L, Li Y, Tang JT, An YF, Wang LL, Shi YY. Donor ABCB1 3435 C>T genetic polymorphisms influence early renal function in kidney transplant recipients treated with tacrolimus. Pharmacogenomics. 2016;17(3):249–257. doi:10.2217/pgs.15.165
   PubMed Web of Science ®Google Scholar
• Liu M. A functional common polymorphism of the ABCB1 gene is associated with chronic kidney disease and hypertension in Chinese. Am J Hypertens. 2013;26(12):1428–1436. doi:10.1093/ajh/hpt126
   PubMed Web of Science ®Google Scholar